Targeted Therapy Options in the Second-line Setting for Patients With Advanced HCC

Download this slideset for expert perspectives on targeted systemic therapy for patients with advanced HCC who have failed an initial systemic regimen.
James M. Cleary, MD, PhD
Format: Microsoft PowerPoint (.ppt)
File Size: 1.30 MB
Released: January 23, 2020

Acknowledgements

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
Eisai
Merck Sharp & Dohme Corp.

Related Content

From Clinical Care Options (CCO), watch video featuring expert perspectives on the use of immunotherapy for HCC

Lipika Goyal, MD Amit G. Singal, MD, MS Physicians: maximum of 1.0 AMA PRA Category 1 Credit Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Released: November 24, 2020 Expired: November 23, 2021

Commentary by Heather McArthur, MD: clinical implications of FDA approval for pembrolizumab plus chemotherapy in PD-L1–positive advanced TNBC from CCO

Heather McArthur, MD, MPH Released: November 20, 2020

Matthew Galsky, MD, discusses the evolving use of immunotherapy in urothelial carcinoma, from Clinical Care Options (CCO)

Matthew Galsky, MD Released: November 19, 2020

In slides from Clinical Care Options (CCO), experts provide insights on the optimal treatment of advanced HCC

Mark Yarchoan, MD Released: November 19, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue